**28 September 2026**

# RESULTS DISCLOSED IN UNAUDITED APPENDIX 4E PRELIMINARY FINAL REPORT COMPARED WITH THE 2026 ANNUAL REPORT

**Patrys Limited (ASX: PAB) ("Patrys" or "the Company")** refers to the Company's unaudited preliminary financial statements lodged with ASX on 31 August 2026 (Appendix 4E) and the Company's Annual Report for the year ended 30 June 2026 lodged with the ASX today (Annual Report). The purpose of this announcement is to provide an explanation for the material differences between the results disclosed in the Appendix 4E Preliminary Final Report and those disclosed in the final Annual Report.

Subsequent to the lodgement of the Appendix 4E and prior to finalisation of the Annual Report, the Company received an independent valuation report in connection with the acquisition of Reliis Pty Ltd. The findings of the independent valuation were incorporated into the finalisation of the acquisition accounting and purchase price allocation under AASB 3 Business Combinations, resulting in the adjustments set out below.

**Consolidated Statement of Profit or Loss and Other Comprehensive Income:**

- Increase in Administration and management expenses of $845 from $1,567,173 to $1,568,018, due to a rounding adjustment arising from the recording of the acquisition of Reliis Pty Ltd.

**Consolidated Statement of Financial Position:**

- Decrease in Goodwill of $788,000 from $820,000 to $32,000 due to the finalisation of the purchase price allocation for the acquisition of Reliis Pty Ltd.
- Decrease in Intangibles (the RLS-2201 in-process research and development ("IPR&D") asset recognised on the acquisition of Reliis Pty Ltd) of $114,000 from $6,750,000 to $6,636,000, reflecting finalisation of the purchase price allocation for the Reliis Pty Ltd acquisition under AASB 3 Business Combinations. The finalisation followed a revised fair value assessment of the Performance Rights issued as part of the acquisition consideration, which reduced total consideration and resulted in corresponding reductions to the carrying amounts of goodwill and the IPR&D intangible asset recognised on acquisition.
- Decrease in Reserves of $901,155 from $4,839,151 to $3,937,996, due to a revised fair value of $1,198,845 (previously $2,100,000) attributed to the Performance Rights issued as part of the consideration for the Reliis Pty Ltd acquisition, following finalisation of the acquisition valuation.

**-Ends-**

This announcement is authorised for release by the Board of Directors of Patrys Limited.

**For further information, please contact:**
**General enquiries**
Samantha South
Chief Executive Officer
P: + 61 421 117 241
info@patrys.com

**Registered Office Address**
168 Stirling Highway
Nedlands WA, 6009

**About Patrys Limited**
Patrys Limited (ASX:PAB) is a clinical-stage company developing an injectable therapy for delirium alongside a differentiated deoxymab platform targeting immune-mediated inflammatory diseases. More information can be found at www.patrys.com.